Management of hepatitis C in patients with chronic kidney disease

Table 3 Meta-analyses on the treatment of chronic hepatitis C in hemodialysis patients

Ref.	Year	Trials (n)	Therapy	n	SVR1
Russo et al[95]	2003	11	IFN	213	33% (21%-51%)
Fabrizi et al[96]	2003	14	IFN	269	37% (28%-48%)
Gordon et al[97]	2008	20	IFN	459	41% (33%-49%)
		5	PEG-IFN	87	37% (9%-77%)
Fabrizi et al[99]	2008	24	IFN	529	39% (32%-46%)
		4	PEG-IFN	116	31% (7%-55%)
Gordon et al[98]	2009	20	IFN	428	45%
Alavian et al[100]	2010	21	IFN	491	39% (32%-46%)
		12	PEG-IFN	279	39% (27%-52%)
Fabrizi et al[101]	2010	16	PEG-IFN	254	33% (24%-43%)
Fabrizi et al[102]	2011	10	PEG-IFN + RBV	151	56% (28%-84%)
Fabrizi et al[103]	2014	11	PEG-IFN + RBV	287	60% (28%-97%)

¹Mean overall estimate for sustained virological response (range). IFN: Interferon; PEG-IFN: Pegylated interferon; RBV: Ribavirin.